var data={"title":"Evaluation and treatment of hypomagnesemia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Evaluation and treatment of hypomagnesemia</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/contributors\" class=\"contributor contributor_credentials\">Alan S L Yu, MB, BChir</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/contributors\" class=\"contributor contributor_credentials\">Stanley Goldfarb, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/contributors\" class=\"contributor contributor_credentials\">Albert Q Lam, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 19, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most of the body's magnesium stores are intracellular, principally within bone. In the extracellular fluid, magnesium can be ionized (free), bound to anions, or bound to protein. (See <a href=\"topic.htm?path=regulation-of-magnesium-balance\" class=\"medical medical_review\">&quot;Regulation of magnesium balance&quot;</a>.) </p><p>The plasma magnesium concentration is not usually measured as part of routine blood tests. Thus, the identification of patients with hypomagnesemia often requires clinical suspicion in patients with risk factors for hypomagnesemia (eg, chronic diarrhea, proton pump inhibitor therapy, alcoholism, diuretic use) or with clinical manifestations of hypomagnesemia (eg, unexplained hypocalcemia, refractory hypokalemia, neuromuscular disturbances, ventricular arrhythmias) [<a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/1,2\" class=\"abstract_t\">1,2</a>]. (See <a href=\"topic.htm?path=causes-of-hypomagnesemia\" class=\"medical medical_review\">&quot;Causes of hypomagnesemia&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-of-magnesium-depletion\" class=\"medical medical_review\">&quot;Clinical manifestations of magnesium depletion&quot;</a>.) </p><p>This topic will review the evaluation and treatment of hypomagnesemia. The regulation of magnesium balance, and the causes and clinical manifestations of hypomagnesemia are presented in detail elsewhere. (See <a href=\"topic.htm?path=regulation-of-magnesium-balance\" class=\"medical medical_review\">&quot;Regulation of magnesium balance&quot;</a> and <a href=\"topic.htm?path=causes-of-hypomagnesemia\" class=\"medical medical_review\">&quot;Causes of hypomagnesemia&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-of-magnesium-depletion\" class=\"medical medical_review\">&quot;Clinical manifestations of magnesium depletion&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients diagnosed with hypomagnesemia, the cause can usually be obtained from the history. (See <a href=\"topic.htm?path=causes-of-hypomagnesemia\" class=\"medical medical_review\">&quot;Causes of hypomagnesemia&quot;</a>.)</p><p>If no etiology is apparent, the distinction between gastrointestinal and renal losses can be made by measuring the 24-hour urinary magnesium excretion or the fractional excretion of magnesium on a random urine specimen.</p><p>The latter can be calculated from the following formula (<a href=\"topic.htm?path=calculator-fractional-excretion-of-magnesium\" class=\"calc calc_professional\">calculator 1</a> and <a href=\"topic.htm?path=calculator-fractional-excretion-of-magnesium-si-units\" class=\"calc calc_professional\">calculator 2</a>): </p><div class=\"formulaContainer\"><div class=\"formula\"><p> &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;UMg &#160;x &#160;PCr<br/> &#160;FEMg &#160; &#160;= &#160; &#160;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &#160; &#160;x &#160; &#160;100 percent<br/> &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; (0.7 &#160;x &#160;PMg) &#160;x &#160;UCr</p></div></div><p>The terms &quot;U&quot; and &quot;P&quot; refer to the urine and plasma concentrations of magnesium (Mg) and creatinine (Cr). The plasma magnesium concentration is multiplied by 0.7 since only about 70 percent of the circulating magnesium is free (not bound to albumin) and therefore able to be filtered across the glomerulus.</p><p>Renal magnesium excretion should be reduced in patients with plasma magnesium depletion. Thus, measurement of 24-hour urinary magnesium excretion or the fractional excretion of magnesemia can help distinguish between gastrointestinal and renal losses of magnesium [<a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/3,4\" class=\"abstract_t\">3,4</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A daily excretion of more than 10 to 30 mg (in a 24-hour urine specimen) or a fractional excretion of magnesium above 2 percent in a person with hypomagnesemia and normal renal function indicates renal magnesium wasting. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>By contrast, a 24-hour urinary magnesium excretion less than 10 mg or a fractional excretion of magnesium less than 2 percent usually indicates an extrarenal source of magnesium losses (typically gastrointestinal).</p><p/><p>In one study of 74 hypomagnesemic patients, for example, the mean fractional excretion of magnesium in patients with hypomagnesemia of extrarenal origin was 1.4 percent (range 0.5 to 2.7 percent) [<a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/4\" class=\"abstract_t\">4</a>]. By comparison, the fractional excretion of magnesium in those with renal magnesium loss was 15 percent (range of 4 to 48 percent). (See <a href=\"topic.htm?path=causes-of-hypomagnesemia\" class=\"medical medical_review\">&quot;Causes of hypomagnesemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Normomagnesemic magnesium depletion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The possibility of normomagnesemic magnesium depletion (in which there is isolated cellular magnesium depletion) should be considered as a possible cause of refractory hypokalemia or unexplained hypocalcemia in patients at high risk for magnesium loss [<a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-of-magnesium-depletion#H1626817\" class=\"medical medical_review\">&quot;Clinical manifestations of magnesium depletion&quot;, section on 'Normomagnesemic magnesium depletion'</a>.) </p><p>One suggested method to detect underlying magnesium depletion is to demonstrate reduced excretion (less than 80 percent over 24 hours) of an infused magnesium load (2.4 <span class=\"nowrap\">mg/kg</span> of lean body weight given over the initial four hours) [<a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/3,5,6\" class=\"abstract_t\">3,5,6</a>]. However, the utility of this test is uncertain. Patients with malnutrition, cirrhosis, diarrhea, or long-term diuretic use typically have a positive test, whether or not they have signs or symptoms referable to magnesium depletion [<a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/7\" class=\"abstract_t\">7</a>]. It seems prudent, therefore, to simply administer magnesium to these patients if they have unexplained hypocalcemia <span class=\"nowrap\">and/or</span> hypokalemia.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The route and dose of magnesium repletion should be selected on the basis of the severity of the clinical manifestations and the degree of hypomagnesemia. </p><p class=\"headingAnchor\" id=\"H22105169\"><span class=\"h2\">Patients with severe symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Symptomatic patients, such as those with tetany, arrhythmias, or seizures should receive intravenous magnesium. Such patients should have continuous cardiac monitoring.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the acute setting, hemodynamically unstable patients (including those with arrhythmias consistent with torsade de pointes or hypomagnesemic hypokalemia), 1 to 2 g <a href=\"topic.htm?path=magnesium-sulfate-drug-information\" class=\"drug drug_general\">magnesium sulfate</a> (8 to 16 meq [4 to 8 mmol]) can be given initially over two to fifteen minutes [<a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/8\" class=\"abstract_t\">8</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-treatment-of-hypokalemia-in-adults#H8647773\" class=\"medical medical_review\">&quot;Clinical manifestations and treatment of hypokalemia in adults&quot;, section on 'Hypomagnesemia and redistributive hypokalemia'</a> and <a href=\"topic.htm?path=acquired-long-qt-syndrome-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">&quot;Acquired long QT syndrome: Clinical manifestations, diagnosis, and management&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In hemodynamically stable patients with severe symptomatic hypomagnesemia (less than or equal to 1 <span class=\"nowrap\">mg/dL</span> [0.4 <span class=\"nowrap\">mmol/L</span> or 0.8 <span class=\"nowrap\">meq/L]),</span> 1 to 2 grams of <a href=\"topic.htm?path=magnesium-sulfate-drug-information\" class=\"drug drug_general\">magnesium sulfate</a> (8 to 16 meq [4 to 8 mmol]) in 50 to 100 mL of 5 percent dextrose in water can be given initially over 5 to 60 minutes followed by an infusion (infusion described in the following bullet) [<a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/8\" class=\"abstract_t\">8</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A simple infusion regimen for nonemergent repletion is 4 to 8 g <a href=\"topic.htm?path=magnesium-sulfate-drug-information\" class=\"drug drug_general\">magnesium sulfate</a> (32 to 64 meq [16 to 32 mmol]) given slowly over 12 to 24 hours [<a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/9\" class=\"abstract_t\">9</a>]. This dose can be repeated as necessary to maintain the plasma magnesium concentration above 1 <span class=\"nowrap\">mg/dL</span> (0.4 <span class=\"nowrap\">mmol/L</span> or 0.8 <span class=\"nowrap\">meq/L)</span>. In the normomagnesemic patient with hypocalcemia, it has been suggested to repeat this dose daily for three to five days [<a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/5,6\" class=\"abstract_t\">5,6</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with renal insufficiency (creatinine clearance less than 30 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>) are at risk for severe hypermagnesemia if large doses of magnesium are given because plasma magnesium concentrations are regulated solely by renal excretion. Thus, we reduce the intravenous magnesium dose in such patients by 50 percent or more and closely monitoring magnesium concentrations. (See <a href=\"#H94929816\" class=\"local\">'Treating patients with impaired renal function'</a> below and <a href=\"topic.htm?path=causes-and-treatment-of-hypermagnesemia#H3\" class=\"medical medical_review\">&quot;Causes and treatment of hypermagnesemia&quot;, section on 'Renal insufficiency'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In children, we use a slow infusion of <a href=\"topic.htm?path=magnesium-sulfate-drug-information\" class=\"drug drug_general\">magnesium sulfate</a>; the dose is 25 to 50 <span class=\"nowrap\">mg/kg</span> (0.2 to 0.4 <span class=\"nowrap\">meq/kg</span> [0.1 to 0.2 <span class=\"nowrap\">mmol/kg])</span> with a maximum single dose of 2 g (16 meq [8 mmol]) [<a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/10,11\" class=\"abstract_t\">10,11</a>]. (See <a href=\"topic.htm?path=significance-of-hypomagnesemia-in-cardiovascular-disease\" class=\"medical medical_review\">&quot;Significance of hypomagnesemia in cardiovascular disease&quot;</a>.) </p><p/><p>(Conversion relationships: 1 mmol = 2 meq = 24 mg of elemental magnesium = 240 mg <a href=\"topic.htm?path=magnesium-sulfate-drug-information\" class=\"drug drug_general\">magnesium sulfate</a>.)</p><p>The magnesium concentration should be measured 6 to 12 hours after each dose of intravenous magnesium. Repeat doses are given based upon the follow-up measurement. </p><p class=\"headingAnchor\" id=\"H1055449\"><span class=\"h3\">Inefficiency of intravenous magnesium supplementation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It must be appreciated that plasma magnesium concentration inhibits magnesium reabsorption in the loop of Henle, the major site of active magnesium transport (see <a href=\"topic.htm?path=regulation-of-magnesium-balance\" class=\"medical medical_review\">&quot;Regulation of magnesium balance&quot;</a>). Thus, when an intravenous magnesium infusion is given, an abrupt but temporary elevation in the plasma magnesium concentration will partially inhibit the stimulus to magnesium reabsorption in the loop of Henle. Thus, up to 50 percent of the infused magnesium will be excreted in the urine. In addition, magnesium uptake by the cells is slow and therefore adequate repletion requires sustained correction of the hypomagnesemia.</p><p>Because of the inefficiencies of intravenous magnesium just described, oral replacement therapy should be given to asymptomatic patients whenever the oral route of administration is available and oral magnesium supplements can be tolerated. </p><p class=\"headingAnchor\" id=\"H22105176\"><span class=\"h2\">Patients with no or minimal symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If available and tolerable, oral replacement should be given to the hypomagnesemic patient with no or minimal symptoms. However, many patients are unable to take oral magnesium or have side effects such as gastrointestinal discomfort and diarrhea. Thus, many hospitalized patients with hypomagnesemia are given intravenous rather than oral magnesium supplementation, even if symptoms are minimal or absent.</p><p class=\"headingAnchor\" id=\"H691295\"><span class=\"h3\">Oral repletion if available and tolerable</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of oral magnesium salts are available. Each differs in the content of elemental magnesium, but all suffer from limited bioavailability. A typical daily dose in a patient with normal renal function is 240 to 1000 mg (20 to 80 meq [10 to 40 mmol]) of elemental magnesium in divided doses.</p><p>Sustained-release preparations have the advantage that they are slowly absorbed and thereby minimize renal excretion of the administered magnesium. Available sustained-release preparations include: <a href=\"topic.htm?path=magnesium-chloride-drug-information\" class=\"drug drug_general\">magnesium chloride</a> containing 64 to 71.5 mg elemental magnesium (eg, Mag Delay, Slow-Mag) and <a href=\"topic.htm?path=magnesium-l-lactate-drug-information\" class=\"drug drug_general\">magnesium L-lactate</a> containing 84 mg elemental magnesium (eg, Mag-Tab SR). Six to eight tablets (30 to 56 meq [15 to 28 mmol]) should be taken daily in divided doses for severe magnesium depletion. Two to four tablets (10 to 28 meq [5 to 14 mmol]) may be sufficient for mild hypomagnesemia. The use of sustained-release preparations may permit the use of lower doses, which minimizes the associated diarrhea (the major dose limiting side effect).</p><p>If a sustained-release preparation is <strong>not</strong> available, <a href=\"topic.htm?path=magnesium-oxide-drug-information\" class=\"drug drug_general\">magnesium oxide</a> 800 to 1600 mg (20 to 40 mmol [40 to 80 meq]) daily in divided doses may be used for moderate to severe hypomagnesemia. Diarrhea frequently occurs with magnesium oxide therapy.</p><p class=\"headingAnchor\" id=\"H691302\"><span class=\"h3\">Intravenous repletion in stable hospitalized patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In some hospitalized patients, oral magnesium supplementation may be unavailable or not tolerable (eg, in postoperative patients who cannot take medications orally). Even if such patients with hypomagnesemia are asymptomatic or minimally symptomatic, intravenous magnesium therapy can be used. </p><p>For routine intravenous repletion or maintenance in the inpatient setting, we use the following regimen in which the dose and rate of repletion depends upon the plasma magnesium concentration [<a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/9,12\" class=\"abstract_t\">9,12</a>]: severe depletion (eg, &lt;1 <span class=\"nowrap\">mg/dL),</span> moderate (1 to 1.5 <span class=\"nowrap\">mg/dL)</span> and mild (1.6 to 1.9 <span class=\"nowrap\">mg/dL</span> combined with suspicion of magnesium depletion) with an estimated repletion dose: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If the plasma magnesium is less than 1 <span class=\"nowrap\">mg/dL</span> (0.4 <span class=\"nowrap\">mmol/L</span> or 0.8 <span class=\"nowrap\">meq/L),</span> give 4 to 8 grams (32 to 64 meq [16 to 32 mmol]) over 12 to 24 hours, and repeat as needed.&nbsp;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If the plasma magnesium is 1 to 1.5 <span class=\"nowrap\">mg/dL</span> (0.4 to 0.6 <span class=\"nowrap\">mmol/L</span> or 0.8 to 1.2 <span class=\"nowrap\">meq/L),</span> give 2 to 4 grams (16 to 32 meq [8 to 16 mmol]) over 4 to 12 hours.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If the plasma magnesium is 1.6 to 1.9 <span class=\"nowrap\">mg/dL</span> (0.7 to 0.8 <span class=\"nowrap\">mmol/L</span> or 1.4 to 1.6 <span class=\"nowrap\">meq/L),</span> give 1 to 2 grams (8 to 16 meq [4 to 8 mmol]) over one to two hours.</p><p/><p class=\"headingAnchor\" id=\"H22105183\"><span class=\"h2\">Correction of the underlying disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The underlying disease should also be corrected, if possible. Patients with hypomagnesemia induced by a thiazide or loop diuretic who cannot discontinue diuretic therapy may benefit from the addition of a potassium-sparing diuretic such as <a href=\"topic.htm?path=amiloride-drug-information\" class=\"drug drug_general\">amiloride</a>. These drugs may decrease magnesium excretion by increasing its reabsorption in the distal nephron [<a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/13\" class=\"abstract_t\">13</a>]. (See <a href=\"topic.htm?path=effect-of-diuretics-on-magnesium-handling-by-the-kidney\" class=\"medical medical_review\">&quot;Effect of diuretics on magnesium handling by the kidney&quot;</a>.) </p><p><a href=\"topic.htm?path=amiloride-drug-information\" class=\"drug drug_general\">Amiloride</a> also may be helpful in conditions associated with persistent urinary magnesium wasting such as Bartter or Gitelman syndrome or <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> nephrotoxicity. In these settings, magnesium repletion alone may be relatively ineffective since raising the plasma magnesium concentration will, as mentioned above, lead to increased magnesium excretion. (See <a href=\"topic.htm?path=bartter-and-gitelman-syndromes\" class=\"medical medical_review\">&quot;Bartter and Gitelman syndromes&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H94929816\"><span class=\"h2\">Treating patients with impaired renal function</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, great caution should be exercised in treating patients who have acute or chronic kidney injury with magnesium containing medications. However, patients with reduced kidney function may require magnesium repletion if they have severe hypomagnesemia (ie, &lt;1 <span class=\"nowrap\">mg/dL</span> [0.4 <span class=\"nowrap\">mmol/L</span> or 0.8 <span class=\"nowrap\">meq/L])</span>. </p><p>There are no published data to guide therapy in such patients, and it is critical that the plasma magnesium concentration be followed closely (ie, after each magnesium dose). In addition, the patient should be monitored for signs of hypermagnesemia such as facial flushing, decreased tendon reflexes, hypotension, and atrioventricular block. (See <a href=\"topic.htm?path=symptoms-of-hypermagnesemia\" class=\"medical medical_review\">&quot;Symptoms of hypermagnesemia&quot;</a>.)</p><p>In the absence of published data, we take the following approach:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A <strong>symptomatic</strong> patient who has moderately reduced kidney function (ie, estimated glomerular filtration rate of 15 to 30 <span class=\"nowrap\">mL/min</span> per 1.73 m<sup>2</sup>) and severe hypomagnesemia should be treated with 2 to 4 g of intravenous <a href=\"topic.htm?path=magnesium-sulfate-drug-information\" class=\"drug drug_general\">magnesium sulfate</a> given slowly over 4 to 12 hours. The plasma magnesium should be checked prior to subsequent doses, and daily if doses are given less frequently. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Asymptomatic</strong> patients who have severe hypomagnesemia and moderately decreased kidney function may be treated with approximately half the dose of the selected oral preparation that is recommended for the patient with normal renal function. The plasma magnesium concentration should be measured before giving a subsequent dose.</p><p/><p>It would be extremely unusual for a patient with no kidney function (ie, on dialysis) to have severe magnesium depletion in the absence of an extrarenal loss such as diarrhea. In such cases, treating the diarrhea may be sufficient to correct the hypomagnesemia. </p><p class=\"headingAnchor\" id=\"H448814222\"><span class=\"h2\">Duration of therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serum magnesium levels usually rise quickly with therapy, but intracellular stores take longer to replete. It is therefore advisable in patients with normal renal function to continue magnesium repletion for at least one to two days after the serum magnesium concentration normalizes.</p><p class=\"headingAnchor\" id=\"H170926976\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-fluid-and-electrolyte-disorders\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Fluid and electrolyte disorders&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H959166297\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypomagnesemia should be suspected in patients who have risk factors for hypomagnesemia (eg, chronic diarrhea, proton pump inhibitor therapy, alcoholism, diuretic use) or clinical manifestations of hypomagnesemia (eg, unexplained hypocalcemia, refractory hypokalemia, neuromuscular disturbances, ventricular arrhythmias). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If an etiology is not apparent from the history, gastrointestinal and renal losses may be distinguished by measuring the 24-hour urinary magnesium excretion or the fractional excretion of magnesium on a random urine specimen (<a href=\"topic.htm?path=calculator-fractional-excretion-of-magnesium\" class=\"calc calc_professional\">calculator 1</a> and <a href=\"topic.htm?path=calculator-fractional-excretion-of-magnesium-si-units\" class=\"calc calc_professional\">calculator 2</a>). The daily excretion of more than 10 to 30 mg or a fractional excretion of magnesium above 2 percent in a patient with normal renal function indicates renal magnesium wasting. (See <a href=\"#H2\" class=\"local\">'Evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normomagnesemic magnesium depletion, or isolated cellular magnesium depletion, may be a cause of refractory hypokalemia or unexplained hypocalcemia. Normomagnesemic magnesium depletion may be detected by demonstrating reduced excretion of an infused magnesium load. Alternatively, magnesium may be empirically administered to patients at high risk for magnesium depletion who have unexplained hypocalcemia <span class=\"nowrap\">and/or</span> hypokalemia. (See <a href=\"#H3\" class=\"local\">'Normomagnesemic magnesium depletion'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The route of magnesium repletion varies with the severity of the clinical manifestations. Patients with severe signs and symptoms of hypomagnesemia should receive intravenous magnesium with cardiac monitoring. Oral replacement should be given to the asymptomatic outpatient, preferably with a sustained-release preparation, in order to prevent abrupt elevations in the plasma magnesium concentration. (See <a href=\"#H22105169\" class=\"local\">'Patients with severe symptoms'</a> above and <a href=\"#H22105176\" class=\"local\">'Patients with no or minimal symptoms'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The underlying disease should also be corrected, if possible. Patients with hypomagnesemia due to renal losses may benefit from the addition of a potassium-sparing diuretic such as <a href=\"topic.htm?path=amiloride-drug-information\" class=\"drug drug_general\">amiloride</a>. (See <a href=\"#H22105183\" class=\"local\">'Correction of the underlying disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In general, patients with reduced kidney function should not receive magnesium-containing medications. However, patients with moderately reduced kidney function who have severe hypomagnesemia may require magnesium repletion. The appropriate regimen for magnesium repletion in such patients depends upon the presence or absence of signs and symptoms of hypomagnesemia. It is critical that the plasma magnesium be followed closely (ie, after each dose), and the patient be monitored for signs of hypermagnesemia. (See <a href=\"#H94929816\" class=\"local\">'Treating patients with impaired renal function'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H704240895\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Gunjeet K Kala Ahluwalia, who contributed to earlier versions of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/1\" class=\"nounderline abstract_t\">Weisinger JR, Bellor&iacute;n-Font E. Magnesium and phosphorus. Lancet 1998; 352:391.</a></li><li><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/2\" class=\"nounderline abstract_t\">Agus ZS. Hypomagnesemia. J Am Soc Nephrol 1999; 10:1616.</a></li><li><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/3\" class=\"nounderline abstract_t\">al-Ghamdi SM, Cameron EC, Sutton RA. Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis 1994; 24:737.</a></li><li><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/4\" class=\"nounderline abstract_t\">Elisaf M, Panteli K, Theodorou J, Siamopoulos KC. Fractional excretion of magnesium in normal subjects and in patients with hypomagnesemia. Magnes Res 1997; 10:315.</a></li><li><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/5\" class=\"nounderline abstract_t\">Ryzen E, Nelson TA, Rude RK. Low blood mononuclear cell magnesium content and hypocalcemia in normomagnesemic patients. West J Med 1987; 147:549.</a></li><li><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/6\" class=\"nounderline abstract_t\">H&eacute;bert P, Mehta N, Wang J, et al. Functional magnesium deficiency in critically ill patients identified using a magnesium-loading test. Crit Care Med 1997; 25:749.</a></li><li><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/7\" class=\"nounderline abstract_t\">Ryzen E, Elbaum N, Singer FR, Rude RK. Parenteral magnesium tolerance testing in the evaluation of magnesium deficiency. Magnesium 1985; 4:137.</a></li><li><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/8\" class=\"nounderline abstract_t\">Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S729.</a></li><li><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/9\" class=\"nounderline abstract_t\">Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm 2005; 62:1663.</a></li><li class=\"breakAll\">Gunn VL, Nechyba C. The Harriet Lane Handbook, 16th ed, Mosby, 2002.</li><li><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/11\" class=\"nounderline abstract_t\">Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.</a></li><li><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/12\" class=\"nounderline abstract_t\">Reed BN, Zhang S, Marron JS, Montague D. Comparison of intravenous and oral magnesium replacement in hospitalized patients with cardiovascular disease. Am J Health Syst Pharm 2012; 69:1212.</a></li><li><a href=\"https://www.uptodate.com/contents/evaluation-and-treatment-of-hypomagnesemia/abstract/13\" class=\"nounderline abstract_t\">Dai LJ, Raymond L, Friedman PA, Quamme GA. Mechanisms of amiloride stimulation of Mg2+ uptake in immortalized mouse distal convoluted tubule cells. Am J Physiol 1997; 272:F249.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 834 Version 21.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H959166297\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EVALUATION</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Normomagnesemic magnesium depletion</a></li></ul></li><li><a href=\"#H4\" id=\"outline-link-H4\">TREATMENT</a><ul><li><a href=\"#H22105169\" id=\"outline-link-H22105169\">Patients with severe symptoms</a><ul><li><a href=\"#H1055449\" id=\"outline-link-H1055449\">- Inefficiency of intravenous magnesium supplementation</a></li></ul></li><li><a href=\"#H22105176\" id=\"outline-link-H22105176\">Patients with no or minimal symptoms</a><ul><li><a href=\"#H691295\" id=\"outline-link-H691295\">- Oral repletion if available and tolerable</a></li><li><a href=\"#H691302\" id=\"outline-link-H691302\">- Intravenous repletion in stable hospitalized patients</a></li></ul></li><li><a href=\"#H22105183\" id=\"outline-link-H22105183\">Correction of the underlying disease</a></li><li><a href=\"#H94929816\" id=\"outline-link-H94929816\">Treating patients with impaired renal function</a></li><li><a href=\"#H448814222\" id=\"outline-link-H448814222\">Duration of therapy</a></li></ul></li><li><a href=\"#H170926976\" id=\"outline-link-H170926976\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H959166297\" id=\"outline-link-H959166297\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H704240895\" id=\"outline-link-H704240895\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>CALCULATORS</h2><div id=\"outlineCalculators\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-fractional-excretion-of-magnesium\" title=\"calculator 1\" class=\"calc calc_professional\">Calculator: Fractional excretion of magnesium</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-fractional-excretion-of-magnesium-si-units\" title=\"calculator 2\" class=\"calc calc_professional\">Calculator: Fractional excretion of magnesium (SI units)</a></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-long-qt-syndrome-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">Acquired long QT syndrome: Clinical manifestations, diagnosis, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bartter-and-gitelman-syndromes\" class=\"medical medical_review\">Bartter and Gitelman syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-and-treatment-of-hypermagnesemia\" class=\"medical medical_review\">Causes and treatment of hypermagnesemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-hypomagnesemia\" class=\"medical medical_review\">Causes of hypomagnesemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-treatment-of-hypokalemia-in-adults\" class=\"medical medical_review\">Clinical manifestations and treatment of hypokalemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-magnesium-depletion\" class=\"medical medical_review\">Clinical manifestations of magnesium depletion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=effect-of-diuretics-on-magnesium-handling-by-the-kidney\" class=\"medical medical_review\">Effect of diuretics on magnesium handling by the kidney</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=regulation-of-magnesium-balance\" class=\"medical medical_review\">Regulation of magnesium balance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=significance-of-hypomagnesemia-in-cardiovascular-disease\" class=\"medical medical_review\">Significance of hypomagnesemia in cardiovascular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-fluid-and-electrolyte-disorders\" class=\"medical medical_society_guidelines\">Society guideline links: Fluid and electrolyte disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=symptoms-of-hypermagnesemia\" class=\"medical medical_review\">Symptoms of hypermagnesemia</a></li></ul></div></div>","javascript":null}